This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Ghana has a free education six-year primary school education system beginning at age 6. The government largely funds basic education comprising public primary schools and public junior high schools. Senior high schools were subsidised by the government until September 2017/2018 academic year that senior high education became free. At the higher education level, the government funds more than 80% of resources provided to public universities, polytechnics and teacher training colleges. As part of the Free Compulsory Universal Basic Education, Fcube, the government supplies all basic education schools with all their textbooks and other educational supplies, like exercise books. Senior high schools are provided with all their textbook requirements by the government. Private schools acquire their educational material from private suppliers.
=== Treatment === In vitro studies have found that several agents are effective against E. floccosum. Disease-specific topical treatments for E. floccosum-related infections are usually effective, commonly with the use of terbinafine, itraconazole, and ketoconazole.
It is clear that using oxygen to completely oxidize glucose provides an organism with far more energy than any oxygen-independent metabolic feature, and this is thought to be the reason why complex life appeared only after Earth's atmosphere accumulated large amounts of oxygen.
Loose connective tissue is characterized by few fibers and cells, and a relatively large amount of ground substance. Dense connective tissue has a smaller amount of ground substance compared to the fibrous material. The meaning of the term has evolved over time.
Sources: en.wikipedia.org
=== Reception === Underworld has a 30% overall approval rating on film-critics' aggregate site Rotten Tomatoes based on 161 reviews, with an average rating of 4.8/10. The site's consensus reads, "Though stylish to look at, Underworld is tedious and derivative." Metacritic, which uses a weighted average, assigned the film a score of 42 out of 100, based on 34 critics, indicating "mixed or average" reviews. Audiences polled by CinemaScore gave the film an average grade of "B+" on an A+ to F scale. Roger Ebert said, "This is a movie so paltry in its characters and shallow in its story that the war seems to exist primarily to provide graphic visuals". However, some critics were more favorable: the New York Daily News praised it as being "stylish and cruel, and mightily entertaining for certain covens out there". Salon reviewer Andrew O'Hehir gave a mixed review, stating, "by any reasonable standard, this dark vampire epic — all massive overacting, cologne-commercial design and sexy cat suits — sucks," but that "at least it gives a crap", conceding that despite the movie's flaws, the complex vampire-werewolf mythology backstory "has been meticulously worked out". The film has since developed a strong cult following.
The duplication events provided material for neofunctionalization to create the novel toxin genes, while gene loss influenced speciation and helped lead to such a wide variety of "chemical cocktails" in rattlesnake venoms. The prevailing theory for the driving force of this evolution is directional selection, where efficacy on prey is selected for. Diversity in prey leads to less specificity in toxins, while highly specialized toxins are more likely to develop when there are few key prey species. However, recently, balancing selection has been indicated to better explain the maintenance of adaptive genetic diversity in venom-related genes, potentially allowing for the rattlesnakes to better keep up in the evolutionary arms race with their prey. Older snakes possess more potent venom, and larger snakes are frequently capable of storing larger volumes of it.
==== Road to war ==== Liu Wenhui's 1990 biography asserts that conflict between the two Lius was almost inevitable. Due to the consolidation of power in Sichuan that had occurred over the 1920s, Liu Wenhui and Liu Xiang had become the two most powerful warlords in the province. Liu Wenhui's assumption of the governorship in 1929 had turned many smaller warlords against him. By controlling the lower reaches of the Yangtze and the Qutang Gorge, Liu Xiang held the geographic advantage over his uncle, having priority in purchasing weapons from abroad (which entered Sichuan through the Yangtze), and had built a navy of three gunboats by fitting merchant ships with iron hulls. This also meant that Liu Xiang could block weapons from reaching Liu Wenhui's upstream domains, an ability that he would use to his advantage. Liu Xiang was also reportedly under the sway of his Taoist mystic advisor, Liu Congyun, who had told him that he was destined to unite the province under his rule. Yet another supposed factor contributing to conflict was the interference of Chiang Kai-shek, who did not want either warlord to become too powerful. Most sources agree that Liu Wenhui's abortive attempt to acquire military aviation assets in 1931 was the spark that led him to conflict with his nephew. Official Chinese sources state that a shipment ordered by Liu of foreign aircraft components worth 2 million yuan was seized by Liu Xiang at the port of Wanxian in Chongqing, leading to heightened tensions between the two Lius.
== Safety == Responsibility for the safety of the subjects in a clinical trial is shared between the sponsor, the local site investigators (if different from the sponsor), the various IRBs that supervise the study, and (in some cases, if the study involves a marketable drug or device), the regulatory agency for the country where the drug or device will be sold. A systematic concurrent safety review is frequently employed to assure research participant safety. The conduct and on-going review is designed to be proportional to the risk of the trial. Typically this role is filled by a Data and Safety Committee, an externally appointed Medical Safety Monitor, an Independent Safety Officer, or for small or low-risk studies the principal investigator. For safety reasons, many clinical trials of drugs are designed to exclude women of childbearing age, pregnant women, or women who become pregnant during the study. In some cases, the male partners of these women are also excluded or required to take birth control measures.
==== Post-translational modification ==== Examples of post-translational modification include phosphorylation, myristoylation and glycosylation. For example, in the response to insulin, the phosphorylation of multiple enzymes, including glycogen synthase, helps control the synthesis or degradation of glycogen and allows the cell to respond to changes in blood sugar. Another example of post-translational modification is the cleavage of the polypeptide chain. Chymotrypsin, a digestive protease, is produced in inactive form as chymotrypsinogen in the pancreas and transported in this form to the stomach where it is activated. This stops the enzyme from digesting the pancreas or other tissues before it enters the gut. This type of inactive precursor to an enzyme is known as a zymogen or proenzyme.
Sources: en.wikipedia.org
== Biography == Jerome Gross was born in New York City on February 25, 1917. In 1939, he graduated from the Massachusetts Institute of Technology. While his scientific interests included astronomy and biology, he chose a career in medicine. He subsequently attended the New York University College of Medicine. After a year as an intern at Long Island College Hospital, he served two years in the Army Medical Corps. Gross believed that clues to diseases such as rheumatic fever would be found in the molecular structure and biology of connective tissue. He returned to M.I.T. to join the laboratory of Francis O. Schmitt as a Research Associate, where he began research on structural macromolecules utilizing chemical and electron microscopical methods. Despite many important observations on hyaluronic acid and elastin, he chose to focus on collagen. He was attracted to Harvard Medical School and the Massachusetts General Hospital by Walter Bauer, who thought that many of the secrets of rheumatoid arthritis and rheumatic fever could be uncovered by similar methods. Gross's pioneering findings that collagen molecules could be extracted from tissues using solutions of neutral salt or dilute acid and reconstituted into various structures opened up the field of collagen research. Gross then began to study collagen structure in animal models of human wound healing. In the late 1950s, he became interested in lathyrism and, with Charles Levene, made the critical observations that lathyrism resulted from abnormal aggregation and defective cross-linking of collagen molecules.
Resistance in gram-negative bacteria is due to mutational variations in the structure and number of porins. In bacteria like Pseudomonas aeruginosa, there is reduced number of porins; whereas in bacteria like Enterobacter species, Escherichia coli and Klebsiella pneumoniae, there are modified porins such as non-specific porins (such as OmpC and OmpF groups) that cannot transport penicillin. Resistance due to PBP alterations is highly varied. A common case is found in Streptococcus pneumoniae where there is mutation in the gene for PBP, and the mutant PBPs have decreased binding affinity for penicillins. There are six mutant PBPs in S. pneumoniae, of which PBP1a, PBP2b, PBP2x and sometimes PBP2a are responsible for reduced binding affinity. S. aureus can activate a hidden gene that produces a different PBP, PBD2, which has low binding affinity for penicillins. There is a different strain of S. aureus named methicillin-resistant S. aureus (MRSA) which is resistant not only to penicillin and other β-lactams, but also to most antibiotics. The bacterial strain developed after introduction of methicillin in 1959. In MRSA, mutations in the genes (mec system) for PBP produce a variant protein called PBP2a (also termed PBP2'), while making four normal PBPs. PBP2a has poor binding affinity for penicillin and also lacks glycosyltransferase activity required for complete peptidoglycan synthesis (which is carried out by the four normal PBPs). In Helicobacter cinaedi, there are multiple mutations in different genes that make PBP variants.
Two preparations of botulinum antitoxins are available for treatment of botulism. Trivalent (serotypes A, B, E) botulinum antitoxin is derived from equine sources using whole antibodies. The second antitoxin is heptavalent botulinum antitoxin (serotypes A, B, C, D, E, F, G), which is derived from equine antibodies that have been altered to make them less immunogenic. This antitoxin is effective against all main strains of botulism.
=== Ontologies and data integration === Biological ontologies are directed acyclic graphs of controlled vocabularies. They create categories for biological concepts and descriptions so they can be easily analyzed with computers. When categorised in this way, it is possible to gain added value from holistic and integrated analysis. The OBO Foundry was an effort to standardise certain ontologies. One of the most widespread is the Gene ontology which describes gene function. There are also ontologies which describe phenotypes.
Le Havre Official website (in French) Official tourism website Archived 23 December 2018 at the Wayback Machine Le Havre Information website (Archive) Le Havre on Lion1906 Slave streets of Le Havre; article on the slave trade here in 17th and 18th century Le Havre on Géoportail, National Geographic Institute (IGN) website (in French) Texts on Wikisource: "Havre, Le". Encyclopædia Britannica. Vol. 11 (9th ed.). 1880. pp. 527–528. "Havre, Le". Encyclopædia Britannica. Vol. 13 (11th ed.). 1911. pp. 83–84. "Havre". The American Cyclopædia. 1879. "Havre". The New Student's Reference Work. 1914. "Havre". Collier's New Encyclopedia. 1921.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.